glp-1 in heart failure The cardiovascular effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Early trials of GLP-1 based
Description
What it doesnt do is optimize that concept or address the full range of metabolic challenges that make weight loss difficult to achieve and even harder to maintain
Kreiner FF, Hovingh GKK, Von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure
Without a digital mechanism to collect and analyze this data, pharma companies risk slower reimbursement and limited market access
This contribution requires GLP-1R signaling in the brain
Managing the side effects makes it more likely youll stay on the medication to reap the benefits
